Core Viewpoint - The company, Qingsong Health, has been struggling to gain traction in the market despite being an early entrant in the crowdfunding space, facing significant competition from its rival, Waterdrop, which has outperformed it in various metrics and successfully listed in the U.S. market [4][10][22]. Group 1: Company Overview - Qingsong Health submitted its prospectus to the Hong Kong Stock Exchange on January 28, 2023, but has yet to complete the listing process [3]. - The company was founded in 2014 and initially gained popularity through its crowdfunding platform, Qingsongchou, which has seen a decline in active users over the years [4][20]. - As of September 30, 2024, Qingsong Health reported 168 million registered users, with active users dropping to 50 million [9]. Group 2: Financial Performance - The annualized premium income from insurance products sold by Qingsong Health has decreased from 1.3 billion RMB in 2022 to 800 million RMB in the first three quarters of 2024 [20]. - The company's revenue from ongoing operations was 394 million RMB in 2022, 490 million RMB in 2023, and 643 million RMB in the first three quarters of 2024 [9]. - The revenue from Qingsong Health's insurance services accounted for 81.5% of total revenue in 2022, but this figure dropped to 37.1% in the first three quarters of 2024 [16]. Group 3: Competitive Landscape - Waterdrop, founded by a former Meituan employee, has surpassed Qingsong Health in market share, capturing 67% of the crowdfunding market compared to Qingsong's 14% [11][12]. - Waterdrop's aggressive marketing strategies, including a "0 fee" model, have contributed to its rapid user growth, while Qingsong Health's slower approach has hindered its competitiveness [13][14]. - The decline in public interest in crowdfunding and the associated trust issues have affected both companies, leading to a decrease in potential customer bases [20][21]. Group 4: Business Model and Challenges - Qingsong Health's business model relies on converting traffic from its crowdfunding platform into insurance and health service revenues, but this model has faced challenges due to declining user engagement [5][15]. - The health services segment has shown growth, with revenues increasing from 59.8 million RMB in 2022 to 398 million RMB in the first three quarters of 2024, but the gross margin has significantly decreased [24]. - The company has faced rising procurement costs in its health services, which have not translated into proportional profit growth, raising concerns about its long-term sustainability [26][29].